Biktarvy Gilead Sciences | Bictegravir / Emtricitabine / TAF | INSTI + NRTI/NtRTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Celsentri ViiV Healthcare | Maraviroc | Entry Inhibitor | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Delstrigo Merck | Doravirine / Lamivudine / Tenofovir DF | NNRTI + NRTI/NtRTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Descovy Gilead Sciences | Emtricitabine / TAF | NRTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Dovato ViiV Healthcare | Dolutegravir / Lamivudine | INSTI + NRTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Edurant Janssen | Rilpivirine | NNRTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Generic TDF/FTC (Emtricitabine/Tenofovir DF) Multiple (Generics) | Emtricitabine / Tenofovir DF | NRTI | Reimbursed | Generic combinations are widely accessible and reimbursed under standard national health policies. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Genvoya Gilead Sciences | Elvitegravir / Cobicistat / Emtricitabine / TAF | INSTI + NRTI/NtRTI + pharmacokinetic enhancer | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Intelence Janssen | Etravirine | NNRTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Isentress Merck | Raltegravir | INSTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Juluca ViiV Healthcare | Dolutegravir / Rilpivirine | INSTI + NNRTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Kaletra AbbVie | Lopinavir / Ritonavir | PI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Odefsey Gilead Sciences | Rilpivirine / Emtricitabine / TAF | NNRTI + NRTI/NtRTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Pifeltro Merck | Doravirine | NNRTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Prezista Janssen | Darunavir | PI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Symtuza Janssen | Darunavir / Cobicistat / Emtricitabine / TAF | PI + NRTI/NtRTI + pharmacokinetic enhancer | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Tivicay ViiV Healthcare | Dolutegravir | INSTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Triumeq ViiV Healthcare | Dolutegravir / Abacavir / Lamivudine | INSTI + NRTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Truvada Gilead Sciences | Emtricitabine / Tenofovir DF | NRTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Vocabria ViiV Healthcare | Cabotegravir | INSTI | Reimbursed | Fully financed through the national health insurance framework via specialized clinic infrastructure. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Rukobia ViiV Healthcare | Fostemsavir | Attachment Inhibitor | Available, not reimbursed | Approved by EMA, but may require special funding requests or is restricted to highly treatment-experienced patients. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Sunlenca Gilead Sciences | Lenacapavir | Capsid Inhibitor | Available, not reimbursed | Approved by EMA, but may require special funding requests or is restricted to highly treatment-experienced patients. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Generic TLD (Tenofovir/Lamivudine/Dolutegravir) Multiple (Generics) | Tenofovir DF / Lamivudine / Dolutegravir | INSTI + NRTI/NtRTI | Not available | Generic combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Generic TLE (Tenofovir/Lamivudine/Efavirenz) Multiple (Generics) | Tenofovir DF / Lamivudine / Efavirenz | NNRTI + NRTI/NtRTI | Not available | Generic combinations are typically not procured as branded single-tablet regimens are widely available. [Source: Local Ministry of Health / ECDC reports] | 14/09/2026 |
Apretude ViiV Healthcare | Cabotegravir (PrEP) | INSTI (Long-Acting PrEP) | Under review | Long-acting injectable cabotegravir with oral lead-in tablets, for pre-exposure prophylaxis. The EU/EEA-wide marketing authorisation of 19 September 2023 does not extend to this country; national registration, supply and reimbursement were not confirmed during this review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/apretude] | 14/09/2026 |
Emtriva Gilead Sciences | Emtricitabine | NRTI | Under review | Emtricitabine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines for HIV-1 treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Andorra. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva] | 14/09/2026 |
Epivir ViiV Healthcare | Lamivudine | NRTI | Under review | Lamivudine is a nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Andorra. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/epivir] | 14/09/2026 |
Eviplera Gilead Sciences | Rilpivirine / Emtricitabine / Tenofovir DF | NNRTI + NRTI/NtRTI | Under review | A once-daily fixed-dose HIV-1 regimen containing rilpivirine, emtricitabine and tenofovir disoproxil; resistance history and viral-load restrictions apply. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Andorra. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera] | 14/09/2026 |
Kivexa ViiV Healthcare | Abacavir / Lamivudine | NRTI | Under review | A fixed-dose NRTI backbone containing abacavir and lamivudine; HLA-B*5701 screening is required before abacavir treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Andorra. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa] | 14/09/2026 |
Norvir AbbVie | Ritonavir | PI + pharmacokinetic enhancer | Under review | Ritonavir is a protease inhibitor used mainly at low dose as a pharmacokinetic enhancer for other protease inhibitors. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Andorra. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/norvir] | 14/09/2026 |
Rekambys Janssen | Rilpivirine | Long-Acting NNRTI | Under review | Long-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing Andorra record for the complete Vocabria / Rekambys regimen is classified as 'Review in Progress (2026)', so this required rilpivirine component uses the same access and reimbursement status. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys] | 14/09/2026 |
Retrovir ViiV Healthcare | Zidovudine | NRTI | Under review | Zidovudine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines; it is now generally a specialised or alternative treatment option. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Andorra. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir] | 14/09/2026 |
Rezolsta Janssen | Darunavir / Cobicistat | PI + pharmacokinetic enhancer | Under review | A fixed-dose combination of darunavir and cobicistat used with other antiretrovirals. EMA's CHMP issued a positive opinion on 25 June 2026 for a dispersible formulation and paediatric use from age 3 years and 15 kg. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Andorra. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta] | 14/09/2026 |
Stribild Gilead Sciences | Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DF | INSTI + NRTI/NtRTI + pharmacokinetic enhancer | Under review | A once-daily fixed-dose HIV-1 regimen containing an integrase inhibitor, pharmacokinetic enhancer and two reverse transcriptase inhibitors. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Andorra. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/stribild] | 14/09/2026 |
Viread Gilead Sciences | Tenofovir DF | NtRTI | Under review | Tenofovir disoproxil is a nucleotide reverse transcriptase inhibitor used with other antiretrovirals for HIV-1 treatment; renal and bone monitoring may be relevant. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Andorra. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/viread] | 14/09/2026 |
Vocabria / Rekambys ViiV Healthcare / Janssen | Cabotegravir / Rilpivirine | Long-Acting ART | Under review | Country-level marketing, supply and reimbursement have not yet been verified. | 14/09/2026 |
Yeytuo Gilead Sciences | Lenacapavir (PrEP) | Capsid Inhibitor (Long-Acting PrEP) | Under review | Twice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The EU/EEA-wide marketing authorisation of 26 August 2025 does not extend to this country; national registration, supply and reimbursement were not confirmed during this review. An identical product, Lenacapavir Gilead, received a positive EMA opinion under the EU-M4all procedure for use outside the EU. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo] | 14/09/2026 |
Ziagen ViiV Healthcare | Abacavir | NRTI | Under review | Abacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy; HLA-B*5701 screening is required before treatment. EMA authorisation confirms the product identity but does not establish registration, market supply or reimbursement in Andorra. No product-specific national reimbursement listing was confirmed during this review; status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen] | 14/09/2026 |